bioAffinity Technologies, Inc. (BIAFW) stock
BIAFWNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 4/3056% below fair value
$0.24+0.00 (0.00%)
Close on Oct 30, 2026Market cap $23.58MP/E –Yield –
bioAffinity Technologies gross margin
Gross margin is gross profit as a percentage of revenue.
bioAffinity Technologies's gross margin for the twelve months ending Sep 30, 2023 was 2.7%. For fiscal 2022 it was 0.1%.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 0.1% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2023 | Sep 30, 2023 | 75.0% | −12.3 |
| Q2 FY2023 | Jun 30, 2023 | 93.7% | +4.9 |
| Q1 FY2023 | Mar 31, 2023 | 0.0% | – |
| Q4 FY2022 | Dec 31, 2022 | 0.0% | – |
| Q3 FY2022 | Sep 30, 2022 | 87.3% | – |
| Q2 FY2022 | Jun 30, 2022 | 88.8% | – |